Processa Pharmaceuticals, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Processa Pharmaceuticals, Inc. (PCSA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $3.29 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-30.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2022-03-30
- Processa Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2021-12-31 was $922.96K.
- Processa Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2021-09-30 was $981.87K, a 496.86% increase year-over-year.
- Processa Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2021-06-30 was $762.60K, a 712.40% increase year-over-year.
- Processa Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2021-03-31 was $620.59K, a 529.00% increase year-over-year.
- Processa Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2021 was $3.29M, a 20.44% increase from fiscal 2020.
- Processa Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2020 was $2.73M, a 434.80% increase from fiscal 2019.
- Processa Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2019 was $510.48K, a 589.25% increase from fiscal 2018.
- Processa Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2018 was $74.06K.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2021-12-31 | $922.96K derived: 10-K 12 month − 3 quarters · filed 2022-03-30 | $1.90M derived: sum of 2 quarters · filed 2022-03-30 | $2.67M derived: sum of 3 quarters · filed 2022-03-30 | $3.29M 10-K · filed 2022-03-30 | |
| 2021-09-30 | $981.87K 10-Q · filed 2021-11-12 | $1.74M derived: sum of 2 quarters · filed 2021-11-12 | $2.37M derived: sum of 3 quarters · filed 2021-11-12 | ||
| 2021-06-30 | $762.60K 10-Q · filed 2021-11-12 | $1.38M derived: sum of 2 quarters · filed 2021-11-12 | |||
| 2021-03-31 | $620.59K 10-Q · filed 2021-11-12 | $308.30K 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | $2.73M 10-K · filed 2022-03-30 | ||||
| 2020-09-30 | $164.51K 10-Q · filed 2021-11-12 | $258.38K derived: sum of 2 quarters · filed 2021-11-12 | $357.04K derived: sum of 3 quarters · filed 2021-11-12 | ||
| 2020-06-30 | $93.87K 10-Q · filed 2021-11-12 | $192.53K derived: sum of 2 quarters · filed 2021-11-12 | |||
| 2020-03-31 | $98.66K 10-Q · filed 2021-11-12 | ||||
| 2019-12-31 | $510.48K 10-K · filed 2021-03-25 | ||||
| 2019-09-30 | $269.13K 10-Q · filed 2020-11-12 | $335.61K derived: sum of 2 quarters · filed 2020-11-12 | $394.16K derived: sum of 3 quarters · filed 2020-11-12 | $417.70K derived: sum of 4 quarters · filed 2020-11-12 | |
| 2019-06-30 | $66.48K 10-Q · filed 2020-11-12 | $125.03K derived: sum of 2 quarters · filed 2020-11-12 | $148.57K derived: sum of 3 quarters · filed 2020-11-12 | $199.10K derived: sum of 4 quarters · filed 2020-11-12 | |
| 2019-03-31 | $58.56K 10-Q · filed 2020-11-12 | $82.09K derived: sum of 2 quarters · filed 2020-11-12 | $132.62K derived: sum of 3 quarters · filed 2020-11-12 | ||
| 2018-12-31 | $23.54K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-06 | $74.06K derived: sum of 2 quarters · filed 2020-03-06 | $74.06K 10-K · filed 2020-03-06 | ||
| 2018-09-30 | $50.53K 10-Q · filed 2019-11-14 | $50.53K 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |